SUZ12 Recombinant Rabbit mAb (一抗) - WB | Bioss

bsm-52749R

重组兔单抗

SUZ12 Recombinant Rabbit mAb

胚胎干细胞抑制蛋白Suz12重组兔单抗

CHET9; IMMAS; JJAZ1; 2610028O16Rik; D11Ertd530e; mKIAA0160; SUZ12_HUMAN; SUZ12; Chromatin precipitated E2F target 9 protein (ChET 9 protein); Joined to JAZF1 protein; Suppressor of zeste 12 protein homolog; KIAA0160; SUZ12_MOUSE; SUZ12 polycomb repressive complex 2 subunit; suppressor of zeste 12 homolog (Drosophila)

Rabbit

A synthesized peptide derived from human SUZ12: 41-96

IgG

Liquid

affinity purified by Protein A

Recombinant

3C1

83 kDa

95 kDa

1mg/ml

0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4℃.

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

UZ12 is a polycomb group (PcG) protein. PcG proteins act by forming multiprotein complexes, which are required to maintain the transcriptionally repressive state of homeotic genes throughout development. PcG proteins are not required to initiate repression, but to maintain it during later stages of development. They probably act via the methylation of histones, rendering chromatin heritably changed in its expressibility. SUZ12 is a component of the PRC2 complex, which methylates Lys-9 and Lys-27 residues of histone H3.
SUZ12 is a component of the PRC2 complex, composed of EED, EZH2, SUZ12/JJAZ1, RBBP4 and RBBP7. This complex is distinct from the PRC1 complex, which contains many other PcG proteins like BMI1, CBX4, CBX8, PHC2, PHC3, SCMH1, RING1 and RNF2. SUZ12 mRNA is upregulated in a number of tumors including breast and colon.

SUZ12

Polycomb protein SUZ12

Component of the PRC2/EED-EZH2 complex, which includes EED, EZH2, SUZ12, RBBP4 and RBBP7 and possibly AEBP2. The minimum components required for methyltransferase activity of the PRC2/EED-EZH2 complex are EED, EZH2 and SUZ12. Component of the PRC2/EED-EZH1 complex, which includes EED, EZH1, SUZ12, RBBP4 and AEBP2. The PRC2 complex may also interact with DNMT1, DNMT3A, DNMT3B and PHF1 via the EZH2 subunit and with SIRT1 via the SUZ12 subunit. Interacts with WDR77. Interacts with histone H1.

Nucleus.

Overexpressed in breast and colon cancer.

Note=A chromosomal aberration involving SUZ12 may be a cause of endometrial stromal tumors. Translocation t(7;17)(p15;q21) with JAZF1. The translocation generates the JAZF1-SUZ12 oncogene consisting of the N-terminus part of JAZF1 and the C-terminus part of SUZ12. It is frequently found in all cases of endometrial stromal tumors, except in endometrial stromal sarcomas, where it is rarer.

Belongs to the VEFS (VRN2-EMF2-FIS2-SU(Z)12) family.
Contains 1 C2H2-type zinc finger.

Polycomb group (PcG) protein. Component of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1 and CDKN2A.